COMP <GO>
AORT vs SGP // EV/EBITDA & P/E VALUATION
Artivion Inc. (NYSE) VS. SpyGlass Pharma Inc. (NASDAQ) • 15-METRIC TALLY: AORT 4
— SGP 1
■ METRIC PARITY
LAST: $23.44 (+2.27%) • MKT CAP: $1.14B
valuation
19.3x
LAST: $32.51 (-1.06%) • MKT CAP: $1.09B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AORT VS. SGP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AORT | SGP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.50% | -35.00% | +39.50 | AORT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.07% | -3.08% | +3.15 | AORT | /fcf-yield <GO> |
| Operating Margin | 7.60% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 2.20% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 13.60% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.46 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 2/9 | +7.00 | AORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.6 | 71.4 | -24.81 | SGP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 98.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.14B | $1.09B | $55.5M | AORT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AORT REV | SGP REV | AORT GROSS % | SGP GROSS % | AORT FCF | SGP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $441.3M | $0 | 64.4% | — | $839.0K | -$33.5M |
| FY 2024 | $388.5M | $0 | 64.0% | — | $11.0M | -$24.0M |
| FY 2023 | $354.0M | — | — | — | $18.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AORT // BETA —
SGP // BETA —